Novo Nordisk secures pill license

Danish drugmaker Novo Nordisk struck a $2.6 billion licensing deal with China’s Hengrui Pharma for global rights to an experimental weight-loss pill.

Der Standard

Battle for the weight-loss pill – Novo Nordisk seals multi-billion deal with China

The Danish pioneer in the weight-loss injection market is grappling with slowing growth and mounting market pressure. A $2.6 billion deal with China is set to push the sector.

Reposts 1 1d

Financial Times

Novo buys rights to Chinese weight-loss pill in $2.6bn deal

Hengrui Pharma’s experimental drug could be taken just once a week

Reposts 0 2d

Handelsblatt

Diet drug: Novo buys license for weight loss pill from Hengrui

The Danish pharmaceutical group places great hopes in an experimental weight loss drug from China. In a multi-billion deal the group secures the worldwide license.

Reposts 0 2d

Add to Home Screen

News, ranked by scholars

Novo Nordisk secures pill license

Battle for the weight-loss pill – Novo Nordisk seals multi-billion deal with China

Novo buys rights to Chinese weight-loss pill in $2.6bn deal

Diet drug: Novo buys license for weight loss pill from Hengrui

Add to Home Screen

News, ranked by scholars

Novo Nordisk secures pill license

Battle for the weight-loss pill – Novo Nordisk seals multi-billion deal with China

Novo buys rights to Chinese weight-loss pill in $2.6bn deal

Diet drug: Novo buys license for weight loss pill from Hengrui

Sign in to LightNews

Sign up to start reading

Connect Bluesky

Connect with Bluesky